Cargando…
Evaluation of a Scenario in Which Estimates of Bioequivalence Are Biased and a Proposed Solution: t(last) (Common)
In bioequivalence (BE) testing, it is the convention to identify t(last) separately for each concentration‐vs‐time profile. Within‐subject differences in t(last) between treatments can arise when assay sensitivity is reached during washout, causing profiles to fall below the limit of quantitation (L...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5064724/ https://www.ncbi.nlm.nih.gov/pubmed/26479406 http://dx.doi.org/10.1002/jcph.663 |
_version_ | 1782460216455987200 |
---|---|
author | Fisher, Dennis Kramer, William Burmeister Getz, Elise |
author_facet | Fisher, Dennis Kramer, William Burmeister Getz, Elise |
author_sort | Fisher, Dennis |
collection | PubMed |
description | In bioequivalence (BE) testing, it is the convention to identify t(last) separately for each concentration‐vs‐time profile. Within‐subject differences in t(last) between treatments can arise when assay sensitivity is reached during washout, causing profiles to fall below the limit of quantitation (LOQ) at different sampling times. The resulting t(last) difference may be systematic, due to true differences in exposure, and/or random, due to measurement noise. The conventional profile‐specific t(last) approach assumes that concentrations in the terminal phase are sufficiently low that use of different t(last) values between treatments within a subject causes negligible bias in the AUC(0‐t) geometric mean ratio (GMR). Here we investigate the validity of this assumption. Using concentration‐vs‐time data following oral inhalation of 50 μg salmeterol as an example data set, we conducted simulations to evaluate whether use of different test/reference AUC timeframes arising from a systematic difference in exposure causes sufficient AUC(0‐t) GMR bias to influence the determination of BE. To ensure that results would be relevant to BE testing, we considered only test/reference relative systemic exposures within the BE window (80.00%–125.00%). We show that use of conventional profile‐specific t(last) exaggerates true differences in systemic exposure; the resulting AUC(0‐t) ratios are biased from true relative exposure by an amount large enough to impact the conclusion of BE. Thus, drugs whose concentrations fall below LOQ during washout may fail BE inappropriately using conventional methods. AUC(0‐t) calculated over a common timeframe within each subject (t(last)[common]) minimizes this bias and harmonizes the statistical analysis of BE. |
format | Online Article Text |
id | pubmed-5064724 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-50647242016-10-19 Evaluation of a Scenario in Which Estimates of Bioequivalence Are Biased and a Proposed Solution: t(last) (Common) Fisher, Dennis Kramer, William Burmeister Getz, Elise J Clin Pharmacol Drug Development In bioequivalence (BE) testing, it is the convention to identify t(last) separately for each concentration‐vs‐time profile. Within‐subject differences in t(last) between treatments can arise when assay sensitivity is reached during washout, causing profiles to fall below the limit of quantitation (LOQ) at different sampling times. The resulting t(last) difference may be systematic, due to true differences in exposure, and/or random, due to measurement noise. The conventional profile‐specific t(last) approach assumes that concentrations in the terminal phase are sufficiently low that use of different t(last) values between treatments within a subject causes negligible bias in the AUC(0‐t) geometric mean ratio (GMR). Here we investigate the validity of this assumption. Using concentration‐vs‐time data following oral inhalation of 50 μg salmeterol as an example data set, we conducted simulations to evaluate whether use of different test/reference AUC timeframes arising from a systematic difference in exposure causes sufficient AUC(0‐t) GMR bias to influence the determination of BE. To ensure that results would be relevant to BE testing, we considered only test/reference relative systemic exposures within the BE window (80.00%–125.00%). We show that use of conventional profile‐specific t(last) exaggerates true differences in systemic exposure; the resulting AUC(0‐t) ratios are biased from true relative exposure by an amount large enough to impact the conclusion of BE. Thus, drugs whose concentrations fall below LOQ during washout may fail BE inappropriately using conventional methods. AUC(0‐t) calculated over a common timeframe within each subject (t(last)[common]) minimizes this bias and harmonizes the statistical analysis of BE. John Wiley and Sons Inc. 2015-12-28 2016-07 /pmc/articles/PMC5064724/ /pubmed/26479406 http://dx.doi.org/10.1002/jcph.663 Text en © 2015, The Authors. The Journal of Clinical Pharmacology Published by‐ Wiley Periodicals, Inc. on behalf of American College of Clinical Pharmacology This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Drug Development Fisher, Dennis Kramer, William Burmeister Getz, Elise Evaluation of a Scenario in Which Estimates of Bioequivalence Are Biased and a Proposed Solution: t(last) (Common) |
title | Evaluation of a Scenario in Which Estimates of Bioequivalence Are Biased and a Proposed Solution: t(last) (Common) |
title_full | Evaluation of a Scenario in Which Estimates of Bioequivalence Are Biased and a Proposed Solution: t(last) (Common) |
title_fullStr | Evaluation of a Scenario in Which Estimates of Bioequivalence Are Biased and a Proposed Solution: t(last) (Common) |
title_full_unstemmed | Evaluation of a Scenario in Which Estimates of Bioequivalence Are Biased and a Proposed Solution: t(last) (Common) |
title_short | Evaluation of a Scenario in Which Estimates of Bioequivalence Are Biased and a Proposed Solution: t(last) (Common) |
title_sort | evaluation of a scenario in which estimates of bioequivalence are biased and a proposed solution: t(last) (common) |
topic | Drug Development |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5064724/ https://www.ncbi.nlm.nih.gov/pubmed/26479406 http://dx.doi.org/10.1002/jcph.663 |
work_keys_str_mv | AT fisherdennis evaluationofascenarioinwhichestimatesofbioequivalencearebiasedandaproposedsolutiontlastcommon AT kramerwilliam evaluationofascenarioinwhichestimatesofbioequivalencearebiasedandaproposedsolutiontlastcommon AT burmeistergetzelise evaluationofascenarioinwhichestimatesofbioequivalencearebiasedandaproposedsolutiontlastcommon |